Gilead Files 8-K on Financial Results & Condition

TL;DR

**Gilead just dropped an 8-K with their latest financial results, so expect some market reaction.**

AI Summary

Gilead Sciences, Inc. filed an 8-K on February 6, 2024, to report its financial results and condition, as well as to include related exhibits. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers the latest official look into Gilead's financial health, which can influence stock price movements and future investment decisions.

Why It Matters

This filing provides investors with the most current official financial information from Gilead Sciences, which is crucial for evaluating the company's performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and does not inherently signal high risk, though the results themselves could be positive or negative.

Analyst Insight

An investor should review the full financial statements and exhibits referenced in this 8-K to understand Gilead's latest performance metrics and assess their impact on the company's valuation and future prospects.

Key Numbers

• $0.001 — par value per share (This is the nominal value assigned to each share of Gilead's Common Stock.)

Key Players & Entities

• Gilead Sciences, Inc. (company) — the registrant filing the 8-K
• February 6, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Gilead Sciences, Inc.
• 000-19731 (dollar_amount) — Commission File No. for Gilead Sciences, Inc.
• 94-3047598 (dollar_amount) — IRS Employer Identification No. for Gilead Sciences, Inc.
• 333 Lakeside Drive, Foster City, California 94404 (company) — address of principal executive offices for Gilead Sciences, Inc.
• 650-574-3000 (dollar_amount) — telephone number for Gilead Sciences, Inc.
• $0.001 (dollar_amount) — par value per share of Common Stock
• GILD (company) — trading symbol for Gilead Sciences, Inc. Common Stock
• The Nasdaq Global Select Market (company) — exchange where Gilead Sciences, Inc. Common Stock is registered

Forward-Looking Statements

• Gilead's stock price (GILD) will react to the financial results disclosed in the full filing. (GILD) — high confidence, target: 2024-02-07

FAQ

From the Filing

0000882095-24-000003.txt : 20240206 0000882095-24-000003.hdr.sgml : 20240206 20240206160407 ACCESSION NUMBER: 0000882095-24-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240206 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24600191 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20240206.htm FORM 8-K gild-20240206 0000882095 false 0000882095 2024-02-06 2024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 6, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Section 2 - FINANCIAL INFORMATION Item 2.02      Results of Operations and Financial Condition. On February 6, 2024 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP